 |
|
|
||||||||||||||
 |
|
|
Tethys is committed to providing the media with timely and accurate information, and we've assembled the following resources to help you learn more about the company and our products.
If you have questions or wish to speak with a representative of the company, please contact a member of the Tethys communications team:
Jay Kerzner, Director of Communications 510-420-6746, jkerzner@tethysbio.com
Hal Mackins, Media Relations for Tethys 415-677-2747, hal.mackins@fkhealth.com
Jul 22, 2010
Tethys Raises $33 Million
Tethys Bioscience, Inc., announced today that the company has recently raised $33 million, comprising $23 million of venture financing and a $10 million working capital loan.
Jul 14, 2010
Diabetes Risk, on a Scale of 1 to 10
A new test is transforming the way some doctors diagnose and treat their patients.
(Technology Review)
Jul 1, 2010
PreDx® featured on CBS Interactive's Smartplanet
CBS Interactive smartplanet video segment focuses on the impact of the PreDx® Diabetes Risk Score on the physician and patient.
Jun 24, 2010
Tethys Announces Issuance of Key Patent Relating to PreDx™ Diabetes Risk Score Test
United States Patent and Trademark Office grants patent to Tethys. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.
Nov 9, 2009
Tethys Bioscience Raises $25 Million in Series D Financing
The financing round is led by aeris Capital with George Rehm taking a seat on the Tethys board.
Oct 20, 2009
Gazing into the Future
(Journal of Life Sciences, Fall 2009)